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Invasive fungal infections are rare but life-threatening infections, most often occurring in 
immunocompromised patients. For a long time, Amphotericin B has been the best choice for treatment, 
because it is fungicidal with a broad antifungal spectrum and minimal risk of resistance development. The 
therapeutic use of amphotericin B has, however, been limited by its toxicity-both acute as well as chronic. To  
counter this, amphotericin B has been encapsulated in liposomes, which reduces its toxicity and allows higher 
doses to be given. Ambisome is a true, spherical, small unilamellar liposome with a median size of 80 nm. The 
pharmacokinetic profile was changed, and the maximum concentration and AUC of amphotericin B after 
AmBisome treatment were greater than those found with the conventional drug. The highest tissue 
concentrations ofAmBisorne were found in the liver and spleen, and less than 1% ofthe administered dose was 
recovered in other organs. At Huddinge University Hospital, we were the first to use and report on the 
experience of AmBisome. We now have more than 12 years’ experience in transplant recipients, with a good 
safety protile, improved rate of curing mycological proven infections and reduced mortality in fungal 
infections. In two placebo-controlled prophylactic trials, we found that AmBisome was effective for 
preventing fungal colonization and invasive fungal infections, respectively, in allogeneic stem cell and liver 
transplantation. In uncontrolled and, more recently, in randomized controlled studies at other centers, 
AmBisome has revealed less toxicity and an efficacy equal or superior to that of the conventional drug in 
treating neutropenia-associated fever and proven invasive fungal infections in both adults as well as in children. 
Although investigators tend to increase the dose used, the optimal dose for probable or proven infection is still 
under debate. Based on our own experience in using AmBisome and the experience at other centers, we can 
conclude that AmBisome represents a major breakthrough in the treatment of invasive fungal infections, 
especially in immunocompromised patients. 
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INTRODUCTION 
Opportunistic fungal infections, mainly caused by Cundida and 
Aspergillus spp., may be life-threatening in severely immuno- 
compromised patients, such as organ and bone marrow 
transplant recipients. Amphotericin B has been the drug of 
choice. Amphotericin B is a macrocyclic polyene antibiotic 
derived from Stveptomyces nodosus and is administered com- 
plexed with deoxycholate [l]. However, the therapeutic use of 
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amphotericin B has been limited by its acute toxicity, 
including headache, chds, fever, nausea, vomiting, diarrhea, 
anorexia, malaise, muscle pain, phlebitis, hypocalemia, anemia, 
bronchospasm, arrhythmias and, above all, nephrotoxicity 
[2,3].  Especially in transplant recipients treated with the 
immunosuppressive drug cyclosporin, therapy with amphoter- 
icin B causes a synergistic nephrotoxicity [4]. To reduce 
toxicity, amphotericin B has been encapsulated in liposomes, 
which allows higher doses [5,6]. In experimental animal 
studies as well as clinical trials, liposomal amphotericin B was 
shown to be effective against invasive fungi [7-lo]. The 
incorporation of amphotericin B into liposomes, this alters the 
pharmacokinetic properties of the drug, which leads to changes 
in tissue distribution, antifungal activity and, most of all, 
tolerabhty. The first preparations of liposomal amphotericin B 
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were prepared at the investigational centers shortly before 
therapy, because they could not be stored for any amount of 
time. However, more than 10 years ago, a lyophilized 
formulation consisting of liposomal amphotericin B incorpo- 
rated into small unilammellar liposomes (mean diameter 45-80 
mm) composed of hydrogenated soy phosphatidyl choline, 
cholesterol and dntearoyl phosphadltylglycerol combined in a 
molar ratio of 2:1:0.8 was introduced. At Huddmge Hospital, 
we were the first to use and report the experience of liposomal 
amphotericin B (AmBisome) [ 111. We have now experienced 
12 years of use of AmBisome in transplant recipients. 
PHARMACOKINETJCS 
Amphotericin B remains the drug of choice for treatment of a 
variety of invasive fungal infections. It is a poorly water- 
soluble polyene. The mechanism of action involves binding to 
membrane sterols of both fungal (ergosterol) and human 
(cholesterol) cells producing pores out of which cell contents 
leak, thus causing cell death. However, amphotericin B has a 
higher affinity to ergosterol than to cholesterol. Amphotericin 
B is fungicidal in vitro with a broad antifungal spectrum with 
minimal risk of development of resistance. It is highly 
lipophilic and administered as a complex with deoxycholate. 
It is poorly absorbed after oral administration and therefore is 
given by slow intravenous infusion diluted in dextrose. 
Electrolytes in the intravenous solution lead to aggregation 
to colloid and so it is administered in dextrose [12]. At a dose 
of 1 mg/kg/day peak concentration achieved is 3.6 mg/L, and 
the area under the curve 34 nig/L/h. Amphotericin B is 
widely distributed in the body with a protein binding up to 
95% [13]. In adults, CSF-concentration is only about 2 4 %  of 
that in serum. In children CSF-concentrations are much 
hgher; up to 90% of concomitant serum concentration has 
been reported. The most important depots in the body are the 
liver, ludney and lungs. The means of elimination of the drug 
is not known and no metabolite has been identified. There has 
been a suggestion that tissue accumulation appears account for 
the majority of drug disposition and the drug has been 
detectable in liver, spleen and kidney for as long as one year 
after termination of therapy. Infusion of amphotericin B is 
poorly tolerated and toxicity is common. Acute toxicity 
includes fever, chills, nausea, vomiting, artralgia, myalgia, 
headache and anaphylaxis. Chronic or dose-dependent 
toxicity is renal toxicity, cardiotoxicity, anemia, potassium 
and magnesium wasting, among which the nephrotoxicity 
usually limits its therapeutic use [12]. 
Because of amphotericin B’s toxicity, the drug has been 
incorporated into a variety of lipid formulations thereby 
reducing the toxic side events and increasing efficacy. 
Depending on the type of lipid incorporation, the pharmaco- 
kinetics of amphotericin B are altered, with the effect varylng 
according to particle size and composition of the complex 
produced. Large structures are rapidly taken up by the 
reticuloendothelial system, whereas a small unilamellar lipo- 
some remains in the circulation for prolonged periods of time. 
AmI3isorne is a true spherical small unilamellar liposome 
with a median size of 80 nm. Each liposome contains 10 
mol.% amphotericin B. The exact mechanism behind the 
reduced toxicity of amphotericin B when gwen as a 
liposomal formulation is not known. Selected transfer of 
amphotericin B from this formulation to the target fungal cell 
wall, avoiding uptake to human cells, is believed to be the 
important mechanism [14]. If the drug is pharmacologically 
active when it is bound to the liposome or if it has to be 
released to reach its site of action is unknown. However, this 
complicates the interpretation of concentrations measured 
since most tests do not discriminate among free or lipid- 
complexed drug levels. 
The maximum concentration of amphotericin B after 1 
mg/kg/day of AmBisome was, in one analysis, up to three 
times that of the conventional drug - 12 us. 3.6 mg/L of 
amphotericin B. The AUC was two times that of conventional 
amphotericin B, 60 vs. 34 mg/L/h. When the dose of 
AmBisome was increased to 5 mg/kg, the peak concentration 
increased to more than seven times (25-59 mg/L) and the 
AUC to more than 15 times (523 mg/L/h) compared with 
conventional drug [13]. Tissue concentrations of AmBisome 
were investigated and tissue samples taken in autopsy cases 
after a total dose of AmBisome ranged between 900 and 3428 
mg. The highest concentrations were found in liver and 
spleen. Concentrations were highly variable but less than 1% 
of the administered dose was recovered in other organs such as 
kidney and heart [ 111. 
PHARMACOKINETICS IN CHILDREN 
The pharmacokinetic profile of AmBisome in children is not 
well studied, but the pharmacokinetics of amphotericin B are 
not the same in infants and children as in adults [15]. As 
compared with adults, children older than 3 months of age 
manifest more rapid clearance of amphotericin B. Premature 
neonates are characterized by extreme individual variation in 
the distribution and clearance of amphotericin B, and thus 
individual serum levels cannot be predlcted with certainty. 
Some neonates continue to accumulate amphotericin B during 
the course of therapy, an observation suggesting that they 
require a dose interval of more than 24 h. Amphotericin B 
toxicity is less severe in infants and chddren than in adults, 
probably because of the more rapid clearance of the dmg from 
children [15]. Studies of pharmacokinetics after administration 
of AmBisome in neonates and children are needed. 
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ARGUMENTS FOR THE USE OF LIPOSOMAL 
AMPHOTERICIN 6 
The arguments for the use of a lipid-associated form of 
amphotericin B are two-fold first, that activity is dose 
dependent with the conventional drug, and that the ease of 
administration of M i s o m e  in particular allows greater doses 
to be administered; second, that toxicity is dose limiting but, 
with the liposomal formulations, there is a marked reduction 
of toxicity and, therefore, the possibility to increase doses. 
Thus, there is an increased therapeutic index with the use of 
the liposomal formulations of amphotericin B. 
Until recently, we have had evaluation difficulties regarding 
lipid formulations of amphotericin B, because there are few 
well-designed trials and available data are based on hetero- 
geneous groups of severely ill patients. Furthermore, treatment 
has been instituted more or less on a compassionate basis, 
because of treatment failures with other antifungal drugs, or 
because of toxicity or the risk of toxicity in patients. However, 
well-performed randomized trials comparing conventional 
drugs with liposomal amphotericin B have recently been 
performed. In the remainder of this article, we will discuss 
compassionate data - ours and those of others - randomized 
comparative data and, finally, treatment in children. 
THE HUDDINGE EXPERIENCE OF AMBISOME 
In the first study, four organ and four bone marrow transplant 
recipients were treated with AmBisome in a compassionate 
basis programme ranging f?om 9 to 48 days (median 15) with a 
median cumulative dose of 963 mg. Maximum dose ranged 
from 0.9 to 2.5 mg/kg. S i x  of the eight patients with proven 
or probable deep fungal infection recovered and were 
discharged from hospital. Two bone marrow transplant 
patients died during therapy. One was negative for fungi at 
autopsy; in the other patient, autopsy was not performed. 
Amphotericin B concentrations taken at autopsy ranged from 
25 to 281 kg/g tissue in bone marrow, liver and spleen, and 
from 0.6 to 8 in lung, heart, muscle and hdney. Two patients 
developed high alkaline phosphatase values during treatment, 
but no other acute side-effects were noted. 
The first units to use AmBisome reported toxicity and efficacy 
[16,17]. These studm included 126 patients who were treated 
for 137 episodes of hngal dection at 43 investigational centres. 
There were 47 females and 79 males. The median age was 35 
years (range 4-87). There were 72 patients with mahgnancies 
(among those 55 with leukemia), 17 organ transplant recipients, 
12 with AIDS and 25 other. Among the patients, 25 were 
recipients of allogeneic or autologous bone marrow. AmBisome 
treatment was instituted after toxicity from previous amphoter- 
icin B treatment in 49 cases, renal insufficiency in 40 and fdure 
of previous antlfungal treatment in 41 instances. Doses of 
AmBisome of 3-5 mg/kg/day were administered. In the safety 
study, 133 episodes of therapy with AmBisome were evaluated 
[16]. Eleven of 71 patients with initially normal serum creatinine 
concentrations showed increased values after AmBisome 
therapy. However, 17 patients among 50 with in i tdy  htgh 
serum creatinine levels recovered normal renal function during 
AmBisome treatment. Hypocalemia was the most common 
adverse event seen in 24 episodes. Nausea and vomiting were 
seen in three and arrhythmia in two. It was concluded that 
AmBisome appeared to be a safe alternative to conventional 
amphotericin B (161. With conventional amphotericin B, acute 
toxicity and side-effects occur in a majority of the patients, even 
in those receiving as little as 0.3 mg/kg/day. 
Some 108 episodes were clinically evaluable; among these 
52 were caused by Candida spp.(although many had Candida in 
the respiratory tract only) and 34 by Aspugillus spp. Ninety- 
nine patients were treated for more than 1 week with a 
maximum dose of 0.7-5 mg/kg/day. Among 64 cases with 
proven invasive infections, 37 (58%) were cured, 12 (19%) 
improved and 15 (23%) Wed to respond. The cure rate in the 
patients with Candida infections was 19/25 (76%), compared 
with 9/28 (32%) in Aspergillus infections (P < 0.01). Fungi 
were eradicated &om a deep site in 35/54 (65%) of 
mycologically evaluable cases. The eradication rate was 83% 
for Candida species, compared with 41% for Aspergillus species. 
Fungi were eradicated in 14/22 patients with leukemia, 518 
with immunodeficiencies, 9/10 with organ transplants, 113 
with dgnanc ie s  other than leukemia and 6/11 others. 
AmBisome tissue concentrations were studied in three autopsy 
cases. High concentrations of AmBisome were seen in liver 
and spleen. The lung showed variable concentrations and low 
concentrations were seen in heart and brain. In the kidney, 
concentrations were intermediate. 
Efficacy evaluation of AmBisome is complicated by 
difficulties in the diagnosis of fungal infections, the poor 
condition of patients and patients' frequent concommitant 
infections. The cumulative dose of AmBisome and the length 
of treatment had no influence on the eradication rate of fungi. 
This may be because patients with poorer prognosis and tho$e 
with a slower response rate were treated with high doses and 
for a longer period of time. Some 37% of the patients died 
within 4 weeks of AmBisome therapy, which emphasizes the 
poor prognosis in the patients included in this study. 
Furthermore, fungal infection was the cause or contributing 
cause of death in 25 patients. However, 16 of 20 patients in 
whom previous amphotericin B had failed were cured by or 
responded to AmBisome [18]. High-risk patients, such as bone 
marrow transplant recipients during the leukopenic phase, are 
often beyond therapy by the time the diagnosis of fungemia is 
made [19,20], so the experience of AmBisome was encoura- 
ging. It led to studies of prophylaxis and empirical therapy. 
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In our initial experience at Huddinge Hospital, 10 trans- 
plant patients receiving AmBisome were compared with 10 
retrospective control patients given conventional amphoter- 
icin B [21]. Each group included eight bone marrow transplant 
recipients, one kidney transplant recipient and one liver 
transplant recipient. Among the patients treated with conven- 
tional amphotericin B, treatment was instituted as a result of 
nine Candida infections and one Aspergillusfumigatus infection. 
In the AmBisome group, treatment was instituted as a result of 
Candida infection in eight of 10 patients. in the amphotericin 
B group, the maximal daily dose ranged from 0.1 to 0.65 mg/ 
kg and was given over 3-32 days. In the AmBisome group, 
maximal daily dose ranged &om 0.9 to 2.3 mg/kg and was 
given over 8-28 days. All patients in the amphotericin B group 
experienced severe toxicity, especially nephrotoxicity, com- 
pared with only one patient with cholestasis in the AmBisome 
group. Only three out of 10 patients in the amphotericin B 
group responded to treatment, seven patients died and six 
patients still had evidence of invasive fungal infection at 
autopsy. In contrast, eight out of nine patients in the 
AmBisome group responded to treatment, and the patient 
who received prophylaxis had a successful course. 
At Huddinge Hospital, we evaluated safety in 187 transplant 
recipients treated for 197 episodes given AmBisome for a 
median of 11 days [22,23]. This comprised our first 5 years’ 
experience of AmBisome. The patients included 89 bone 
marrow transplant recipients, 64 liver transplant recipients, 20 
renal transplant recipients, 10 recipients of combined kidney 
and pancreas transplants, two recipients of liver and pancreas 
transplants, one recipients of a single pancreas transplant and a 
recipient of a bone marrow transplant and a subsequent liver 
transplant. Median age was 36 years (range 0.5-72). AmBi- 
some was instituted for verified invasive fungal infections in 34 
cases, suspected invasive fungal infection in 80 cases and as 
prophylaxis in 83 cases. AmBisome was given for a median of 
11 days (range 1-112) with a maximum daily dose of 
1.49 0.7 mg/kg/day (mean f SE). The total cumulative 
dose of AmBisome was 1.1 5 1.78 g. Side-effects definitely 
attributed to AmBisome therapy included low potassium 
(n=3),  low back pain (3), dyspnoea (2), allergic rash (l), 
nausea and vomiting (l), confusion (l), rise in alkaline 
phosphatase (1) and cholecystitis (l), with an overall incidence 
of 13/197 (7%). AmBisome was discontinued due to side- 
effects in six (3%) of the cases. Side-effects possibly due to 
AmBisome therapy included low potassium (36%), increase in 
serum creatinine (31%), rise in alkaline phosphatases (26%) and 
fever (3%). The overall mean increase in serum creatinine was 
20%. Other possible side-effects, such as headache, abdominal 
pain, rash, rise in bilirubin, cramps and pancreatitis, were seen 
in single patients. In these instances, Amsisome may have 
potentiated the toxici,ty of other drugs. AU patients were 
treated with various potentially toxic drugs, including 
cyclosporin, some also with nephrotoldc antibiotics, diuretics 
and others. However, the side-effects of AmBisome were mild 
and manageable in most patients. None of the patients treated 
with AmBisome had an anaphylactic reaction. However, 
anaphylactic reactions caused by AmBisome have been 
reported [23]. From our study, it was concluded that 
AmBisome provided a great contrast to the situation with 
conventional amphotericin 3, where acute toxicity and side- 
effects occurred in a majority of the patients. Although mild 
side-effects were seen in Misome-treated patients, these 
were rapidly reversible in most patients. As an example, 1 
week after discontinuation of AmBisome, normalization or 
improvement was seen in the serum potassium and serum 
creatinine values of 66% of the patients. 
Invasive fungal infection has been the cause of death in 11% 
of our patients during the amphotericin B era [20]. We 
therefore compared invasive fungal infections verified at 
autopsy during three dif5erent periods in our bone marrow 
transplant programme [ a ] .  Before 1985, the patients were 
treated with monotherapy as prophylaxis against graft-vs.-host 
disease (GVHD). During this period, 30% of the patients 
developed moderate-to-severe GVHD and autopsy-proven 
invasive fungal infection was 15/129 (12%). Between October 
1985 and December 1988, effective prophylaxis against GVHD 
combining methotrexate and cyclosporin, or giving T-cell 
depleted transplants was introduced [25-271. With this more 
effective therapy, only 13% of the patients developed moderate- 
to-severe acute GVHD. However, the rate of autopsy-proven 
invasive fungal infection was still high (11/98, 11%). However, 
after the introduction of AmBisome in January 1989, the 
autopsy-proven invasive hngd infections decreased to 121199 
(6%), which was sigrdcantly decreased ( P  < 0.05), compared 
with the two previous periods. The 6equency of autopsy in 
patients with a transplant was 73%, 69% and 62% in these three 
eras. As not all patients who died underwent autopsy, this 
finding has to be interpreted with some caution. 
AMBISOME PROPHYLAXIS 
Because of the difficulties in diagnosing invasive fungal 
infections, it was thought that prophylaxis with AmBisome 
would be the optimal strategy in bone marrow and liver 
transplant recipients, who are at high risk of invasive fungal 
infection. A randomized double-blind study of AmBisome 
prophylaxis was performed in bone marrow transplant 
recipients [28]. AmBisome was given when the neutrophil 
count had decreased to <0.5 x 109/L and was continued 
until neutrophils recovered to this level, or an infection or a 
toxicity end-point was reached. Thirty-six patients received 
1 mg/kg/day of AmBisome and 40 patients received placebo 
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daily. Patient characteristics and clinical course were similar 
between the two groups. Fungal colonization decreased in 
the AmBisome group while it increased in the placebo 
group. By the end of prophylaxis, 8/24 (33%) of the patients 
receiving AmElisome were colonized, compared with 18/29 
(62%) of the placebo patients (P=0.05).  Five and seven 
patients on AmBisome or placebo, respectively, were with- 
drawn due to a presumed fungal infection. Proven fungal 
infection occurred in one patient receiving AmBisome 
(Candida guilliermondii), compared with three patients receiv- 
ing placebo (Cundidu guilliermondii 11; Candida ulbicuns I). 
AmBisome was well tolerated at a dose of 1 mg/kg/day and 
there was no statistical difference in side-effects between the 
two study groups. However, three patients in the M i s o m e  
group experienced allergc reactions related to infusion of the 
drug. All three patients experienced flushing, erythema, 
breathmg problems and headache. After discontinuation of 
the drug, the reactions resolved in all three patients. Four 
additional patients experienced adverse events, possibly 
related to AmBisome. One patient had confusion and fever. 
Another experienced nausea, one-third had vomiting and 
chills, and all these patients later received AmElisome for 16- 
21 days without new adverse events. The fourth patient had 
erythema and cholecystitis after 6 days of prophylaxis that 
resolved. In the placebo group, two patients had fever. 
Comparing pre-with post-treatment blood chemistry values, 
the AmBisome group had significant increases in blood urea 
nitrogen, 61% vs. 114% ( P  < 0.01) and creatinine 55% us. 
83% ( P  < 0.001). There was no difference in i.v. 
supplementation of potassium between AmBisome or 
placebo-treated patients during the study. The conclusion 
from this study was that AmBisome prophylaxis was well 
tolerated during the aplastic period in bone marrow 
transplant recipients. However, it was not completely 
effective in preventing Candida infection. Therefore, further 
studies are needed concerning aspergillosis and candidiasis 
before any recommendations can be made. 
Among solid organ transplant recipients, orthotopic liver 
transplant recipients have had the highest reported incidence 
of invasive fungal infections ranging between 6% and 42% 
[29,30]. Most infections occur within the first postoperative 
month. The gastrointestinal tract is a major reservoir of 
Candida, which explains the hgh incidence of invasive 
candidiasis in liver transplant recipients who receive extensive 
surgery, often involving the intestines. Therefore, a rando- 
mized double-blind study of AmBisome was performed [31]. 
Seventy-seven liver transplant recipients received 5 days of 
prophylaxis starting during the transplantation procedure with 
either AmBisome 1 mg/kg/day or placebo. Among 40 
AmBisome-treated patients, no invasive Cundidu infection 
was seen during the first month, compared with five invasive 
Cundidu ulbicans infections among 37 control patients (P  < 
0.05). Furthermore, one placebo patient experienced Asper- 
gillus niger pneumonia. Thus, the overall incidence of invasive 
fungal infection was 0/40 in the AmBisome group vs. 6/37 
(16%) in the placebo group (P  < 0.01). Patient survival did 
not differ between the two groups and at 30 days it was 92% 
us. 94% for the AmBisome and the placebo-treated patients, 
respectively. Side-effects related to AmBisome included 
transient thrombocytopenia in two patients and low back 
pain in one patient. Regarding blood chemistry, alkaline 
phosphatase increased significantly in the AmBisome-treated 
patients who had 3.3 times the upper normal value at 30 days, 
as compared with 1.5 times in the placebo group (P  < 0.01). 
Other laboratory tests &d not differ between the two groups. 
The costs for antifungal drugs in the AmBisome group was 
US$32912 for prophylaxis and USf20050 for treatment of 
suspected invasive fungal infection, a total of USf52 962. In 
the placebo group, the costs were US$37943 for treatment 
of verified invasive fungal infections and USf15033 for 
suspected invasive fungal infection with a total of US$52 976. 
However, the cost for prophylaxis in the AmBisome group 
was US85031 less than the cost for treatment of verified 
invasive fungal infection in the placebo group. This study 
showed that AmBisome prophylaxis was well tolerated and 
effective in preventing invasive fungal infection following liver 
transplantation. 
This study was followed by a long-term follow-up where all 
patients who had received 5 days of prophylaxis were followed 
for at least 1 year [32]. Late invasive fungal infection occurred 
in four AmBisome-treated patients between 30 days to 1 year 
after transplantation with a median onset at day 81 (range 39- 
325). Three patients had Aspetgillus, all found at autopsy. One 
patient developed a Candida ulbicuns cholangitis, which was 
successfully treated. In the placebo group, five patients 
developed late invasive fungal infections, four of which were 
candidiasis and one aspergdosis with a median onset at day 
150 (range 41-365). All except one patient with Cundida 
ulbicans peritonitis died. Thus, during the first year, signifi- 
cantly fewer patients [4] developed invasive fungal infection in 
the AmBisome group, compared with 11 in the placebo group 
( P  < 0.05), resulting in a one-year probability of invasive 
fungal infection of 11% vs. 29% in the AmBisome and placebo 
group, respectively. Patient survival at 1 year was 80% in the 
AmBisome group, compared with 78% in the placebo group, 
respectively (ns). 
From our experience at Huddinge Hospital in bone marrow 
and organ transplant patients using AmBisome, we can 
conclude that AmBisome is safe and gives few side-effects. It 
is also effective and represent a major breakthrough in the 
treatment of invasive fungal infections. A concern is the high 
costs [33]. 
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OTHER CENTERS' EXPERIENCE 
During the last 10 years several studies &om single centers with 
small patient numbers have shown AmBisome to be effective 
in infections other than those caused by Candida and Aspergillus 
spp. Nine of these noncomparative studles with immuno- 
compromised patients treated for proven fungal infection were 
pooled together; of these three studies had mycological 
eradication as an endpoint [34]. For 121 cases of candidiasis, 
a median eradication rate of 79% (range 13-100%) was 
documented in 41 cases of aspergdosis, the median eradication 
rate was 67% (range 41-loo%), and in 11 cases of other fungal 
infections, the eradication rate was 78%. 
AmBisome was shown to be effective in AIDS patients 
suffering from cryptococcosis, in five small noncomparative 
trials. Doses ranged between 1 and 3 mg/kg/day for a median 
of 16-35 days [35]. The mycological cure rate ranged between 
67 and 85% with a me&an of 71%. In one randomized trial of 
AmBisome 4 mg/kg vs. conventional amphotericin B 70.7 
mg/kg for a median of 21 days, the mycological cure rate was 
sigmficantly better for AmBisome, 79 vs. 38% for amphoter- 
icin B. 
COMPARATIVE STUDIES 
More recently, controlled studies in which ArnBisome has 
been compared with conventional amphotericin B or Abelcet 
have been performed. There are four randomized studies in 
neutropenic patients in which AmBisome was used as 
empirical treatment and compared with conventional ampho- 
tericin B in two and to Abelcet in one and finally one study of 
treatment of mould infections. 
The first study was a multicenter study in England in a total 
of 338 patients out of whom 204 were children [34]. 
Neutropenic patients with fever of unknown origin not 
responding to 96 h of broad spectrum antibiotics were 
randomized to receive either M i s o m e  1 or 3 mg/kg/day 
and compared with amphotericin B at a dose of 1 mg/kg/day. 
The study was analyzed by intention to treat. Success was 
defined as a minimum of three days with fever lower than 
38°C continuing to study end as indicated by recovery of 
neutrophil count. Toxicity both as related adverse events and 
severe adverse events were significantly fewer in both 
ArnBisome arms, as compared with conventional drug. 
Nephrotoxicity in patients not receiving concomitant nephro- 
toxic agents, defined as a doubling of the patients baseline 
creatinine level was not observed in the AmBisome 1 mg/kg/ 
day arm whereas the incidence was 3% in the AmBisome 3 
mg/kg/day arm and 23% in the conventional drug arm (P < 
0.01). Responses, both total and response despite persistent 
neutropenia, were statistically not different for AmBisome at a 
dose of 1 mg/kg/day, compared with conventional ampho- 
tericin B. However, with AmBisome 3 mg/kg/day, there was 
a significantly better response, compared with the conven- 
tional drug both during neutropenia and overall, 61% and 
64%, vs. 32% and 49%, respectively (P  < 0.05). 
The second study of fever of unknown origin was 
performed as a blinded comparative multicenter study in the 
USA in a total of 687 patients, in whom half were bone 
marrow transplant recipients [37]. In this study, treatment was 
started with either AmBisome at 3 mg/kg/day, or amphoter- 
icin B 0.6 mg/kg/day with a possibility to increase or decrease 
the doses. Treatment was started if fever of unknown origm 
not responding to 96 h of broad-spectrum antibiotic treatment 
during neutropenia was present. In this study success required 
that the drug should not be permanently discontinued because 
of toxicity or lack of efficacy. Patients should survive 7 days 
after the study drug was introduced and fever should resolve 
during the neutropenic period. 
There was significantly less toxicity with ArnBisome as 
compared with the conventional drug. Fewer patients had 
infusion-related adverse events in the form of fever, 17% vs. 
44%, chills or rigon, 18% us. 54%, for AmBisome or the 
conventional drug, respectively. Nephrotoxicity, defined as 
two times upper normal limit value, was significantly less 
frequent among patients receiving AmBisorne-19% compared 
with 34% for patients receiving amphotericin B ( P  < 0.001). 
With regard to efficacy, there were no differences between the 
study arms with regard to composite success rate (50% and 
49%), survival rate (93% and 90%), or resolution of fever 
during neutropenia, 58% and 58% for AmBisome and 
amphotericin B, respectively. However, there were signifi- 
cantly fewer emerging fungal infections with AmBisome 
compared with amphotericin B, 5% vs. 9% (P= 0.021). 
A study was perfxtned in the Netherlands evaluating the 
hypothesis that there would be a better outcome of 
neutropenia-associated invasive fungal infections if higher 
doses of lipid formulations of amphotericin B were used [38]. 
AmBisome was compared with amphotericin B in a 
randomized multicenter study in the treatment of documented 
and suspected invasive hngal infections during neutropenia. 
AmBisome was gwen at a dose of 5 mg/kg/day compared with 
amphotericin B at a dose of 1 mg/kg/day. A total of 106 
patients, out of which 66 were evaluable for efficacy, were 
included in the study. Of these, nine patients had documented 
fungemia, 17 patients had documented invasive mould 
infections and 40 patients had suspected pulmonary aspergd- 
losis. Despite a dose of AmBisome of 5 mg/kg, toxicity was 
scarce and significantly fewer patients had kidney function 
deterioration compared with the conventional drug. Serum 
creatinine elevation at 14 days after treatment was 1.4 k 5% for 
AmBisome, compared with 86 & 9% with the conventional 
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drug ( P  < 0.001). Therapy had to be stopped or changed due 
to toxicity in only three and two patients, respectively, in the 
AmBisome arm, compared with seven and eight patients with 
the conventional drug (P=O.O31, P < 0.001). Efficacy was 
better for AmBisome and complete responses at the end of 
treatment was seen in 44% of the patients receiving AmBisome, 
compared with 18% of the patients receiving the conventional 
drug (Ps0.03). Responses in proven fungal infections with 
complete responses was significantly better with AmBisome, 
64% vs. 17% with the conventional drug (P=O.O2). 
Thus to conclude, three randomized trials comparing 
AmBisome with conventional amphotericin B has shown that 
AmBisome was less toxic and as effective or superior to 
conventional drug in treating neutropenia-associated fever and 
fungal infection of unknown origin. However, the optimum 
dose for probable or established hngal infection is still 
under debate. 
A study by the EORTC Invasive Fungal Infectious Co- 
operative Group comparing two doses of AmElisome for the 
treatment of invasive aspergillosis in neutropenic patients 
showed no benefit for a higher dose [39]. This study was 
performed in 120 patients out of whom 87 were eligible and 
evaluable. Doses compared were 1 vs. 4 mg/kg/day of 
AmBisome. Clinical responses were documented in 64% of 
the patients receiving 1 mg/kg/day and 48% of the patients 
receiving 4 mg/kg/day. With regard to radiological responses 
and the number of deaths due to invasive aspergillosis, there 
were no differences within the two study arms. 
Although this study did not show any advantage of a higher 
dosage, a tendency among investigators today is to increase the 
dose used initially when treating patients with a suspected or 
proven fungal infection. Obviously, this will have a great 
economic impact, since AmBisome is much more expensive 
than the conventional drug, or any other antifungal drug 
available at present. However, efficacy and toxicity must be 
taken into consideration when costs are analyzed. This 
becomes evident in one study between two lipid formulations 
that have recently been presented. This was a US multicenter 
double-blind randomized head to head comparison of 
AmBisome and Abelcet in 244 neutropenic patients with 
unresolved fever after 3 days of antibiotic treatment [40]. The 
study was powered for safety and not for efficacy. Patients 
were randomized to receive either AmBisome 3 or 5 mg/kg/ 
day or Abelcet 5 mg/kg/day. AmBisome had significantly less 
acute adverse events such as fever, chills and rigors compared 
with Abelcet. Furthermore, significantly lower rates of 
nephrotoldcity was seen, 14.1% and 14.8% for AmBisome 3 
and 5 mg compared with 42.3% for Abelcet. Toxicity-related 
discontinuation of therapy was less fiequent with AmBisome 3 
and 5 mg, 12.9% and 12.3% vs. 32.1% for Abelcet. Although 
not powered for efficacy, successful responses were seen in 
40% and 42% of Aml3isome 3 and 5 m g k g  treated compared 
with 33.3% of Abelcet-treated patients. 
THERAPEUTIC USE IN THE MANAGEMENT OF FUNGAL 
INFECTIONS IN CHILOREN 
In most cases, intravenous amphotericin B is still the antifungal 
drug of choice in children. Owing to the manifest individual 
differences both in clinical and immunological status, there is 
no standard treatment. Dosage and duration of treatment are 
empirical. To avoid toxicity, AmBisome is indicated in 
patients who have failed to respond to conventional 
amphotericin B, patients who develop nephrotoxicity after 
receiving conventional amphotericin B, or patients in whom 
conventional amphotericin B is contraindicated because of 
renal impairment. Comparative trials are necessary to define 
the pharmacokinetics of AmBisome and optimal dosages in 
different kinds of immunocompromised children such as 
neonates, children with cancer and children receiving organ or 
bone marrow transplants. 
AMBISOME PROPHYLAXIS IN CHILDREN 
Tollemar and co-workers (1993, 1994) have, in two placebo- 
controlled, double-blind randomized trials, presented their 
experience with AmBisome prophylaxis in allogeneic bone 
marrow transplant and liver transplant recipients (both 
chrldren and adults). The incidence of verified IF1 was in 
the AmBisome groups 3% and 0%, compared with 8% and 
16% in the placebo groups, respectively [28,32]. 
In a retrospective study, RingdCn and co-workers presented 
their experience with AmBisome prophylaxis and therapy for 
invasive hngal infections in children undergoing organ or 
allogeneic bone-marrow transplantation [41]. AmBisome was 
given as prophylaxis in 30 episodes in 25 children for a median 
of 14 days (3-46) in a dose of 1 mg/kg/day (range 0.6-4.3), 
with the total dose a median of 0.20 g [0.025-2.61. 
Prophylaxis, 1 mg/kg/day was given during the neutropenic 
phase after BMT, when the polymorphonuclear count (F'MN) 
was below 0.5 x 109/L. In liver transplant patients, 1 mg/kg/ 
day was given during the first 5 days. AmBisome was well 
tolerated as prophylaxis in transplanted children and few acute 
tolac side-effects were seen. The commonest probable side- 
effect of AmBisome in children given prophylaxis were, 
decreased serum potassium levels in 40%, renal toxicity in 
37%, and increased alkaline phosphatase levels in 30%. 
AMBISOME TREATMENT IN CHILDREN 
AmBisome has been reported to be effective against systemic 
infection in chddren, including infants. This has been 
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demonstrated in several studies. In children with systemic 
mycoses who had failed to respond to or could not tolerate 
amphotericin B [42]; 11 children (median 7) received 
amphotericin B (6) or AmBisome (5). In both groups, three 
patients had highly suspected or proven fungal infection, Most 
of these were leukemic patients and seven had received bone 
marrow transplants. None of those treated with AmBisome 
died of fungal infection. The maximal dose of AmBisome used 
in this group was 6 mg/kg and the cumulative dose given was 
122-311 mg/kg. 
Two very low birth-weight infants treated with AmBisome 
recovered without sequelae. One of these cases had neonatal 
candidemia due to C. utbicam, the other disseminated 
aspergillosis. The infants tolerated doses up to 5 mg/kg daily 
very well [43]. 
Nowoczyn and co-workers reported, in 1992 AmBisome 
treatment in 10 neutropenic children with hematological 
malignancies and systemic fungal infection [44j. The median 
age of the chlldren was 8.5 years (range 1.5-16.5 years). Six 
children were pretreated with conventional amphotericin-3 
plus flucytosine. The change to AmBisome in these children 
was due to toxicity in four and/or progression of pulmonary 
infiltrates in two children, respectively. Seven children 
suffered from candidosis and three from aspergdosis. Seven 
of 10 children responded to AmBisome and survived. 
The AmBisome dose was 1.5-2.5 mg/kg/day. Median 
duration oftreatment was 15 days (4-35 days). AmBisome was 
well tolerated. 
In 1994, Emminger et al. presented a study of 16 children, 
aged 3 months to 18 years of age (median 7.5 years), with 
cancer, who were treated with AmBisome [45]. Four had 
highly suspected or verified invasive fungal infection (C. 
albicam or C. glabruta), and 12 children received empirical 
treatment [45]. Fifteen of these children were severely 
granulocytopenic. Three of the four patients with highly 
suspected or verified infections were cured. The patient who 
failed had severe aplastic anemia with C. glabruta candidemia. 
Although large cumulative doses were given, no organ 
function abnormalities attributable to AmBisome were 
detected in any of 10 long-term survivors over a median 
observation time of 36 months (range 30-44 months). 
Ringdtn and colleagues, have included 14 immunocom- 
promised children in a noncomparative study [46]. One child 
received treatment four times, and a total of 17 treatment 
episodes were stuhed. Median age was 14 years (range 9 
months-16 years). Nine children had proven invasive fungal 
infection (IFI) - Candida in six cases and Aspetgillus in three 
cases, and eight patients had suspected IFI. Among the eight 
cases with suspected IFI, s ix  were clinically cured. Among the 
nine cases with proven IFI, seven were clinically cured (78%). 
Of the two failures, one boy had leukemia and an infection 
caused by C. krusei. The other had chronic granulomatous 
disease and Aspergillus spp. in lung and liver. 
Hovi and colleagues reported fungal osteomyelitis due to 
Aspergillusflavus (2) and Saccharomyces cmisiue (1) in the jaws of 
three children on immunosuppressive chemotherapy [47]. 
One child with A.  f l a w s  received AmBisome 1 mg/kg and 
underwent surgery and survived. 
Pasic and colleagues reported that the use of AmBisome was 
safe in bone marrow transplantation for primary immunodefi- 
ciency in 15 paediamc patients [48]. Ringdkn and co-workers 
(1997), have in a retrospective study, presented their experience 
with AmBisome therapy for invasive fimgal infections in 
children undergoing transplantation [41]. AmBisome was given 
as treatment for suspected invasive fungal infection (IFI) in 33 
and for verified invasive fungal infection in 12 patients. Of 31 
children with suspected IFI, fever disappeared in 21 (68%). In 
documented cases treated for 5 days or more, the clinical cure 
rate was 86%. Erahcation of fungi from a deep site was venfied 
in 8/10 and patient survival 1.5 years to more than 7 years post- 
treatment was 7/12 (58%). AmBisome was well toierated as 
therapy in transplanted children. 
AMBISOME TREATMENT OF NEONATES 
Weitkamp and colleagues have reported the outcome and 
nephrotoxicity of treatment with AmBisome in 21 very low 
birth-weight (VLBW) infants [49j. The median gestational age 
was 25 weeks (range 23-31) with a median birth-weight of 
730 g (range 450-1370). In 19 patients, a positive culture for 
Candida spp. was obtained and in two it was negative. Candida 
albicam was found in seven patients, C. parapsilosis in two and 
in one C .  parapsilosis, C. tropiculis and C. kmsei. All but one 
infant survived. All 19 patients with a verified infection had 
fungal eradication and clinical recovery. Antifungal therapy 
was started a median of 13 days (range 1-49) after birth. The 
medan dose given was 2.6 mg/kg/day (range 1-5), and the 
median duration of the therapy was 28 days (range 11-79), 
corresponding to a median cumulative dose of 71 mg/kg 
(range 12-271). Hypokalemia was observed in 30% before, 
and 15% during AmBisome treatment. Median maximum 
dady potassium supplementation did not exceed doses usually 
recommended for VLBW infants. The median of the 
maximum creatinine levels before treatment was 121 pmol/ 
L (range 71-221) and fell to 68 pmol/L (range 31-171) during 
treatment and 46 pmol/L (range 26-62) 21 days after 
termination of therapy. 
Scarcella and co-workers report AmBisome treatment 
results for neonates with a verified deep fungal infection 
[49]. Some 40 preterm and four full-term newborn i&n& 
were treated. Thirty-one were infected with Candida albicam 
(70%) and others with Pickia carsonii, C. pampsilosis, C. sake, C. 
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humicola and C. guilliemondii. The initial d a y  dose of 
AmBisome was 1 mg/kg of body weight; this was increased 
stepwise by 1 mg/kg to a maximal dosage of 5 mg/kg 
according to the patient’s clinical condition. Administration of 
AmBisome was effective in 72.7% of patients (in all full-term 
and 28 preterm newborn infants). Five of six cases of 
meningitis recovered, and 63.6% of 33 VLBW infants 
survived. The initial AmBisome dose of 1 mg/kg/day 
eradicated the fungal infection in only two infants (5%). In 
the 12 unsuccessfully treated infants, Aagnosis was made later 
than in surviving infants (24 f 13 vs. 20 11 days of life). 
The postmortem blood culture revealed C. albicans in eight 
cases, and P. carsonii, C. humicola, C. parapsilosis and C. 
guilliermondii in the other four cases. The duration of 
intravenous AmBisome therapy ranged from 7 to 49 days, 
the mean treatment duration was 22 8 days. The initial daily 
dosage of AmBisome was 1 mg/kg of body weight; this was 
increased stepwise by 1 mg/kg to a maximal dosage of 5 mg/ 
kg according to the patients’ clinical condition. Hypokalemia 
were observed in 16 infants during treatment, but this 
condition was always transient and responded readily to 
potassium supplementation. No side-effects were observed. 
AmBisome treatment of neonatal fungal infection is 
effective and safe. Randomized clinical trials are required to 
establish the most effective administration protocol for 
AmBisome, i.e. the starting dosage, the maximum effective 
dosage and the cumulative dosage, and to verify whether the 
preparation should be associated with another antifungal agent. 
AMBISOME FOR THE TREATMENT OF VISCERAL LEISHMA- 
NlASlS 
AmBisome was shown to be effective in visceral leishmaniasis 
(kcla azar) in six noncomparative trials in a total of 307 patients 
with doses rangmg between 1 and 5 mg/kg/day over 7-21 
days [34]. Responses in immunocompetent patients were 97- 
100% and few relapses were seen at 12 months follow-up. 
Response in AIDS patients were 82-88%, but the majority of 
patients relapsed between 2 and 22 months after treatment was 
discontinued. 
AmBisome, administered in a variety ofregimens over 7-21 
days, is a generally effective treatment for visceral leishmaniasis 
in immunocompetent children, including those aged < 2 years 
[34]. DiMartino and co-workers reported treatment of visceral 
leishmaniasis in 106 immunocompetent children with AmB- 
some [SO]. The study group consisted of 55 boys and 51 girls, 
3-months to 14-years old, with a mean age of 2.5 years. The 
purpose of the study was to optimize the balance between 
duration of treatment and total dose of drug capable of 
erahcating infection. Chldren were enrolled and assigned 
alternately to one of four dose groups. 
The authors concluded that the optimal regimen in 
immunocompetent children with Leishmania infntum visceral 
leishmaniasis is a total dose of 18 mg/kg of AmBisome given as 
3 mg/kg per day for 5 days, followed by 3 mg/kg administered 
as an outpatient regimen on day 10 [50]. Treatment was well 
tolerated and no adverse events were reported. In the chddren 
who failed or relapsed after only 15 mg/kg, all were cured by a 
total dose of 30 mg/kg. 
ECONOMIC IMPACT OF AMBISOME THERAPY 
In any discussion about antifungal treatment, the cost of 
liposomal amphotericin is brought up as the main objection to 
its use. Clearly, the acquisition cost of AmBisome is much 
greater that that of conventional amphotericin B. However, 
cost-benefit assessment of a more expensive antifungal agent 
should not be restricted only to acquisition costs. Instead, the 
potential impact on hospital cost savings by less toxicity and 
improved patient tolerability should be taken into account. 
However, so far, very few pharmacoeconomic studies have 
been performed with regard to antifungal treatment. The first 
with AmBisome was performed in 1992 at our center, where 
58 organ and bone marrow transplant recipient were 
compared with regard to treatment with the conventional 
drug or AmBisome [51]. This study revealed improved 
survival from invasive fungal infections at dlscharge from 
hospital for kidney and pancreas recipients, and 51% 
involvement for bone marrow and liver transplant recipients 
with AmBisome compared with retrospective patients receiving 
conventional amphotericin B treatment. Improved survival 
was also seen at 2.5 years follow-up, in favor of AmBisome 
treatment. The calculated cost per life-year gained ranged in 
these patients between USJ620 000 and 26 000; this is less than 
US$27000, which, at that time, was the cost-effective 
threshold for a year of ‘well life’ gained. 
A group &om The Netherlands performed another economic 
evaluation, in the form of a decision analysis model, to evaluate 
outcome, cost and cost effectiveness of three different strategies 
according to data extracted &om a fever of unknown origin study 
in the UK [52]. First-line therapy was given for 10 days and, if 
unsuccessful after 5 days, then it was complemented with second- 
line therapy also for 10 days. The therapies analyzed were 
conventional amphotericin B followed by AmBisome, i.e. 3 mg/ 
kg/day, or AmBisome 1 mg/kg/day followed by 3 mg/kg/day 
or AmBisome 3 mg/kg/day followed by 5 mg/kg/day. With the 
efficacy figures found in UK data, AmBisome treatment in 
children at a dose of 1 mg/kg/day was less expensive than the use 
of conventional amphotericin B, i.e. US$lO 134 vs. US$10 445. 
However, in adult patientx, AmBisome at either dose of 1 and 3 
mg/kg/day was more expensive than the conventional drug - 
US$l5 509 and US1620 024 compared with US$13 674. 
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One problem with all these studes is that they only regard 
drug costs and disregard eventual extra costs caused by 
toxicity. More recently, some stuhes that take toxicity into 
account have been published. One study evaluated the 
economics of AmBisome as first-line empirical antifungal 
therapy using itemized hospital billing data from the 
randomized US study of AmBisome v5. amphotericin B 
[53]. A total of 414 patients from 19 centers were entered into 
this study, which covered costs from first dose of study 
medication until discharge from the hospital. Hospital costs 
were sigmficantly higher for all patients who received 
AmBisome, i.e. US048 962 vs. US043 183 ( P =  0.022). How- 
ever, when the costs for study drugs were not included, the 
costs were lower for patients who had received AmBisome, 
i.e. US039 648 vs. US043 048. The authors conclude that this 
is mainly because of nephrotoxicity, which occurred more 
frequently in patients who had received the conventional 
drug, and this renders a longer hospital stay and incurs higher 
hospital costs. In their sensitivity analysis which reconciled 
differences in the rate of nephrotoxicity between cost sample 
and clinical study populations, the breakeven cost for 
AmBisome was US$87/50 mg vial for all patients and 
US$112/50 mg vial for allogeneic stem cell transplant patients. 
Toxicity also has an impact on economics using the different 
lipid formulations of amphotericin B. An evaluation of the 
pharmocoeconomics of AmBisome us. Abelcet was performed 
based on two US studies on empirical treatment in febrile 
neutropenic patients [53]. Abelcet at 5 mg/kg was associated 
with a higher incidence of nephrotoxicity compared with 
AmBisome at either dose of 3 or 5 mg/kg. Based on a decision 
analysis model using neprotoxicity, dialysis and drug acquisi- 
tion costs as primary outcomes, total hospital costs were lowest 
using AmBisome 3 mg/kg (US$47 747) compared with 5 mg/ 
kg (US$53033) and Abelcet at 5 mg/kg (US$52 133). 
With the present pharmacoeconomic studies it becomes 
evident that adhtional studies are needed and that only 
loolung at drug acquisition costs will be a narrow way of 
lookmg at antifungal treatment. So far, no study has evaluated 
the economic impact of patient suffering caused by toxicity 
(irrespective of the morbidlty associated with this). 
CONCLUSION 
Conventional amphotericin B has been regarded as the 
standard of treatment for invasive fungal infections, despite 
the high mortality among immunocompromised patients. For 
the last decade, the liposomal formulation of amphotericin B, 
AmBisome, has been available and the picture has changed. 
Do we see a shift in treatment? 
It is notoriously difficult to study antifungal treatment in a 
scientifically rigorous manner. This is evident with all early 
compassionate studies, pooled patient materials or small local 
patient series reported for safety and efficacy as well as for 
economy. Despite this, AmBisome has revealed without 
question an improved safety profile over conventional 
amphotericin B. Thls has enabled us to push dosing upwards 
with an improved therapeutic index. Outcomes in immuno- 
compromised children and adults are certainly equivalent and 
often superior to conventional therapy in both uncontrolled as 
well as in the most recent controlled randomized stuhes. The 
improved outcome is, however, not without cost. Recent 
pharmacoeconomic studies clearly show that it is not enough 
to take into account only acquisition costs. In some patient 
categories, expensive treatment with AmBisome seems to be 
worthwhile. However, many questions remain, such as optimal 
dosing, total dose and when to both start and stop treatment. 
Thus, more well-controlled studies are greatly needed. 
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